Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6092239rdf:typepubmed:Citationlld:pubmed
pubmed-article:6092239lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:6092239lifeskim:mentionsumls-concept:C1299003lld:lifeskim
pubmed-article:6092239lifeskim:mentionsumls-concept:C0003364lld:lifeskim
pubmed-article:6092239lifeskim:mentionsumls-concept:C0040233lld:lifeskim
pubmed-article:6092239pubmed:issue5lld:pubmed
pubmed-article:6092239pubmed:dateCreated1984-12-13lld:pubmed
pubmed-article:6092239pubmed:abstractTextVarious studies were conducted to evaluate the effects of timolol, an S-enantiomer, relative to its R-enantiomer upon intraocular pressure and related ocular systems in the rabbit. The R-enantiomer was about one-third as potent as timolol in displacing 3H-dihydroalprenolol binding to iris-ciliary body tissue, reducing aqueous humor formation, and lowering intraocular pressure of alpha-chymotrypsin hypertensive eyes. In contrast, the R-enantiomer was 50 to 90 times less potent than timolol in antagonizing the effects of isoproterenol on pulmonary and atrial beta-adrenergic receptors. The data indicate that the R-enantiomer may lower intraocular pressure in man at concentrations less likely than timolol to block extraocular beta-adrenergic receptors. Finally, to account for the differential effect of the R-enantiomer upon ocular as opposed to extraocular beta-adrenergic receptors, it is tentatively suggested that this agent may also act upon a population of ocular beta-adrenergic receptors showing relatively poor stereoselectively.lld:pubmed
pubmed-article:6092239pubmed:languageenglld:pubmed
pubmed-article:6092239pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6092239pubmed:citationSubsetIMlld:pubmed
pubmed-article:6092239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6092239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6092239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6092239pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6092239pubmed:statusMEDLINElld:pubmed
pubmed-article:6092239pubmed:issn0721-832Xlld:pubmed
pubmed-article:6092239pubmed:authorpubmed-author:LottiV JVJlld:pubmed
pubmed-article:6092239pubmed:authorpubmed-author:StoneC ACAlld:pubmed
pubmed-article:6092239pubmed:authorpubmed-author:GrossD MDMlld:pubmed
pubmed-article:6092239pubmed:authorpubmed-author:ShareN NNNlld:pubmed
pubmed-article:6092239pubmed:authorpubmed-author:HallR ARAlld:pubmed
pubmed-article:6092239pubmed:authorpubmed-author:SchmittCClld:pubmed
pubmed-article:6092239pubmed:authorpubmed-author:GautheronPPlld:pubmed
pubmed-article:6092239pubmed:issnTypePrintlld:pubmed
pubmed-article:6092239pubmed:volume221lld:pubmed
pubmed-article:6092239pubmed:ownerNLMlld:pubmed
pubmed-article:6092239pubmed:authorsCompleteYlld:pubmed
pubmed-article:6092239pubmed:pagination234-8lld:pubmed
pubmed-article:6092239pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:meshHeadingpubmed-meshheading:6092239-...lld:pubmed
pubmed-article:6092239pubmed:year1984lld:pubmed
pubmed-article:6092239pubmed:articleTitleR-enantiomer of timolol: a potential selective ocular antihypertensive agent.lld:pubmed
pubmed-article:6092239pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6092239lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6092239lld:pubmed